Accurate measurement of viral clearance in early phase antiviral studies in COVID-19.
Wongnak P. et al, (2025), J Infect Dis
Within-host modeling of primaquine-induced hemolysis in hemizygote glucose-6-phosphate dehydrogenase deficient healthy volunteers.
Watson JA. et al, (2025), Antimicrob Agents Chemother, 69
Tuberculosis preventive therapy: scientific and ethical considerations for trials of ultra-short regimens.
Walker TM. et al, (2025), Lancet Infect Dis
Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV).
Jittamala P. et al, (2025), EClinicalMedicine, 80
Probabilistic classification of late treatment failure in uncomplicated malaria
Mehra S. et al, (2025)
Advancing the chemotherapy of tuberculous meningitis: a consensus view.
Wasserman S. et al, (2025), Lancet Infect Dis, 25, e47 - e58
Modeling the within-host dynamics of Plasmodium vivax hypnozoite activation: An analysis of the SPf66 vaccine trial.
Mehra S. et al, (2024), Proc Natl Acad Sci U S A, 121
Rectal artesunate: lives not saved.
White NJ. et al, (2024), Trans R Soc Trop Med Hyg, 118, 639 - 641
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
Schilling WHK. et al, (2024), PLoS Med, 21
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV).
Wongnak P. et al, (2024), Lancet Infect Dis, 24, 953 - 963
Lineage-informative microhaplotypes for recurrence classification and spatio-temporal surveillance of Plasmodium vivax malaria parasites.
Siegel SV. et al, (2024), Nat Commun, 15
Transmission-blocking activities of artesunate, chloroquine, and methylene blue on Plasmodium vivax gametocytes.
Chaumeau V. et al, (2024), Antimicrob Agents Chemother
Phase 2 pilot trial to optimise pharmacometric evaluations in Chagas disease (CHARM: CHAgas disease PharMacometrics)
Cruz CV. et al, (2024), Wellcome Open Research, 9, 342 - 342